Induction of Dormancy in Cryptococcus neoformans In Vitro: The HypNOS Protocol.

Cryptococcus neoformans Dormant cells Hypoxia In vitro dormancy protocol Normoxia Reactivation Resuscitation Viable but nonculturable phenotype

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2024
Historique:
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: ppublish

Résumé

Cryptococcus neoformans is the second major cause of death in patients with HIV. During a latent infection, this pathogenic fungus survives in the host for years without causing symptoms of active disease. Upon favorable conditions, such as immunosuppression due to HIV infection, or other conditions (steroid use or organ transplantation), the yeast may reactivate and cause active cryptococcosis. Hence, dormancy is an important phase in the pathogenesis of C. neoformans. Additionally, C. neoformans also persists during antifungal treatment and causes disease recurrence, which is a major medical problem, especially in low- and middle-income countries. To survive in the host, yeast cells must react to the stresses they are exposed to and generate a cellular response that is favorable for yeast survival. A prominent strategy used by C. neoformans to combat challenging surroundings is dormancy, which may translate into a viable, but nonculturable phenotype (VBNC). This chapter describes an in vitro protocol to generate and characterize dormant Cryptococci.

Identifiants

pubmed: 38758328
doi: 10.1007/978-1-0716-3722-7_22
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

349-358

Informations de copyright

© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Alanio A (2020) Dormancy in Cryptococcus neoformans: 60 years of accumulating evidence. J Clin Investigation 130:3353–3360. https://doi.org/10.1172/jci136223
doi: 10.1172/jci136223
Kobayashi M, Murata K, Hiroshi HO et al (2004) Cryptococcosis: long-lasting presence of fungi after successful treatment. Acta Derm Venereol 84:320–321. https://doi.org/10.1080/00015550410025868
doi: 10.1080/00015550410025868 pubmed: 15339084
Spitzer ED, Spitzer SG, Freundlich LF et al (1993) Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 341:595–596. https://doi.org/10.1016/0140-6736(93)90354-j
doi: 10.1016/0140-6736(93)90354-j pubmed: 8094831
World Health Organization (2022) WHO fungal priority pathogens list to guide research, development and public health action. https://www.who.int/publications/i/item/9789240060241 . Oct 25th 2022
Alanio A, Vernel-Pauillac F, Sturny-Leclère A et al (2015) Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. MBio 6:e02580–e02514
doi: 10.1128/mBio.02580-14 pubmed: 25827423 pmcid: 4453510
Hommel B, Sturny-Leclère A, Volant S et al (2019) Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. PLoS Pathog 15:e1007945. https://doi.org/10.1371/journal.ppat.1007945
doi: 10.1371/journal.ppat.1007945 pubmed: 31356623 pmcid: 6687208
Oblinger JL, Koburger JA (1975) Understanding and teaching the most probable number technique
doi: 10.4315/0022-2747-38.9.540
Calcott PH, Postgate JR (1972) On substrate-accelerated death in Klebsiella aerogenes. J Gen Micro 70:115–122. https://doi.org/10.1099/00221287-70-1-115
doi: 10.1099/00221287-70-1-115
Mukamolova GV, Kaprelyants AS, Kell DB et al (2003) Adoption of the transiently non-culturable state—a bacterial survival strategy? Adv Microb Physiol 47:65–129. https://doi.org/10.1016/s0065-2911(03)47002-1
doi: 10.1016/s0065-2911(03)47002-1 pubmed: 14560663
de Castro RJA, Rêgo MTAM, Brandão FS et al (2022) Engineered fluorescent strains of Cryptococcus neoformans: a versatile toolbox for studies of host-pathogen interactions and fungal biology, including the viable but nonculturable state. Microbiol Spectr 10:e01504–e01522. https://doi.org/10.1128/spectrum.01504-22
doi: 10.1128/spectrum.01504-22 pubmed: 36005449 pmcid: 9603711

Auteurs

Ruchi Agrawal (R)

Department of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.

Aude Sturny-Leclère (A)

Department of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.

Raffael J A de Castro (RJA)

Department of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.

Alexandre Alanio (A)

Department of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France. alexandre.alanio@pasteur.fr.
Laboratoire de parrasitologie-Mycologie, Hôpital Saint-Louis, Paris, France. alexandre.alanio@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH